Sign in

Dr.Uma Borate The Ohio State University / James Cancer Hospital

@beatalleukemia.bsky.social
338 followers 182 following 19 posts

Clonal Hematopoesis,MDS,AML @OSUCCC_James Acute Leukemia Clinical Section Head and Clinical Research Director. Girl Mom, Vegetarian, Avid Reader, Traveller & Adventurer

PostsRepliesMedia
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 24/04/2025
How fortunate are we to have @kimrynrathmell.bsky.social bring her wealth of experience & outstanding leadership to @osucccjames.bsky.social @osuwexmed.bsky.social ! Welcome to #BuckeyeNation Dr. Rathmell! @osuhematology.bsky.social
030
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 10/04/2025
The closest I’m ever going to come to a National Football Championship Trophy ! 🙏🏽 @Peletonia @Huntington_Bank @OhioStateFB Proud to be a Peletonia funded @osuhematology.bsky.social @osucccjames.bsky.social Researcher & part of #BuckeyeNation
030
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 09/04/2025
What other kinds of presentations are there (other than fabulous ? ) Clearly, I have been attending the wrong conferences so far without fabulous presentations 😂
010
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Anand Patel @anand-88-patel.bsky.social · 06/04/2025
a nice analysis from the BEAT AML study outlining molecular characteristics of adults >60 with AML www.nature.com/articles/s41...
032
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Barnes & Noble @barnesandnoble.com · 06/04/2025
Hi. Books are incredibly important. Please let them be.
223199652925
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Anand Patel @anand-88-patel.bsky.social · 02/04/2025
helpful sub-group analysis of Aza + Ven studies looking at treatment-naive t-AML and AML arising from MDS or CMML! www.nature.com/articles/s41...
041
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 02/04/2025
Very proud to have played a role in this study with my study chair Dr. Eric Huselton from University of Rochester - please consider your patients for this study @osuhematology.bsky.social @osucccjames.bsky.social @swog.org @ash.hematology.org
023
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Mark Cuban @mcuban.bsky.social · 28/03/2025
If you know anyone that takes Sprycell, please let them know !!!
29175331966
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Anand Patel @anand-88-patel.bsky.social · 28/03/2025
A great @bloodjournal.bsky.social paper by @beatalleukemia.bsky.social et al on clinical trial eligibility for patients with MDS! ashpublications.org/blood/articl...
231
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 28/03/2025
Thrilled to see our effort on behalf of @ic_MDS group out in @BloodJournal about reducing clinical trial eligibility barriers for our MDS patients. Commentary by Lionel Ades on ‘ releasing the brake’ on eligibility criteria. @Dr_AmerZeidan #mdssm ashpublications.org/blood/article/…
121
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Bruce Levine, Ph.D. 🇺🇦 @bllphd.bsky.social · 28/03/2025
Happy CD3 CD28 T Cell Stimulation Day to all who celebrate
072
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 26/03/2025
Calling all hematologists - how are you interpreting the results of the TRAIN trial vs the SAHARA trial in patients with blood cancers & acute cerebral bleeding events ? jamanetwork.com/journals/jam... www.nejm.org/doi/full/10.... @shematologist.medsky.social @bloodman.bsky.social
jamanetwork.com
Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury
This randomized clinical trial assesses the effect of a liberal vs a restrictive hemoglobin threshold for red blood cell transfusion on unfavorable neurological outcome in patients with acute brain in...
000
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 25/03/2025
Sunset & snow makes for good hunting.#springbreak
010
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 20/03/2025
I would be the second to last one 😂
010
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Anand Patel @anand-88-patel.bsky.social · 18/03/2025
a very nice review in AJH on considerations of MPN management in women! onlinelibrary.wiley.com/doi/full/10....
021
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 19/03/2025
👇🏾
000
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
American Society of Hematology @ash.hematology.org · 19/03/2025
Could adjusting a simple blood test reference range save patients unnecessary stress? Recent research highlights Duffy null-associated neutrophil count (DANC) and the risk it imposes on certain ancestral backgrounds. Enroll in the ASH course: bit.ly/duffynull #HemeSky #Hematology #MedSky
Researchers at Brigham and Women's Hospital, Boston, recently found that ANC in 120 people with the Duffy null blood group can range from 1210-5390 microliters: significantly lower than most institutional reference rangesHistorically, ANC reference ranges have had a lower limit of 2000 microliters, but these were based on studies in populations with European ancestry, in whom the Duffy null phenotype is rare.2/3 of people in the USA who self-identify as African-American have the Duffy null phenotype. It is also more common in people of Middle East and North African ancestry.
2227
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Ohio State Hematology @osuhematology.bsky.social · 12/03/2025
The 2025 @castleconnolly.bsky.social Exceptional Women in Medicine is out!🎉This honor celebrates🔝female physicians for their leadership & expertise. 👏 Congrats to the OSUCCCJames Heme honorees: Jennifer Woyach Uma Borate @beatalleukemia.bsky.social Alice Mims Ashley Rosko Kami Maddocks Kerry Rogers
011
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 06/12/2024
EST to PST problems. Awake 3 hrs before #ASH24 activities start but very excited for our Scientific Workshop on DCTs & AI from 2-5 pm today! If you are a trial sponsor , investigator , statistician or involved in any clinical research- this one is ‘A must attend’ ! #DCTs
020
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
American Society of Hematology @ash.hematology.org · 05/12/2024
Great haiku! The excitement for #ASH24 will power us through this early morning!
021
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 05/12/2024
Waking up before the crack of dawn EST to PST Excited for #ASH24 #ASHaiku
180
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 26/11/2024
Our Friday Scientific Workshop on Real World DCTs in Hematology &AI has a fantastic line up of speakers : clinical trialists ( IIT PIs included) statisticians, pharma sponsors, & regulatory experts discussing all things practical about hematology DCTs - join us ! 👇🏾#ASH24
042
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 26/11/2024
go.bsky.app/Avv8xad I made this starter pack for any myeloid malignancy academics to find others - please share & add to this !
173
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Ryan Elliott @ryanelliott.bsky.social · 26/11/2024
🩸 CHIP, CCUS, & ICUS quick definitions: CHIP - leukemia-associated gene mutation w/ VAF ≥ 2% - normal blood counts - no dx of another hematologic malignancy CCUS = CHIP with ≥ 1 cytopenias ICUS ≥ 1 cytopenias + 🚫 identifiable mutation #hemesky #MedSky #IMsky
pubmed.ncbi.nlm.nih.gov
ICUS/CCUS/CHIP: basics & beyond - PubMed
Patients presenting with idiopathic cytopenia with non-diagnostic marrow morphology and a normal karyotype pose a diagnostic and therapeutic challenge. Additional diagnostic information from mutation ...
062
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 26/11/2024
📢 Don’t miss Ohio State’s 2024 Scarlet and Gray Reception at the National ASH Meeting! 🌟 Network, connect, and celebrate with us. 🗓️ Register now: osu.az1.qualtrics.com/jfe/form/SV_8H… #ASH24 #BuckeyePride #ScarletAndGray
010
Dr.Uma Borate The Ohio State University / James Cancer Hospital @beatalleukemia.bsky.social · 23/11/2024
www.nejm.org/doi/full/10.... Such an important article addressing why certain groups may receive differing medical treatment including access to clinical trials.
nejm.org
The Duffy Null Phenotype — Addressing a Source of Discrimination in Cancer Care | NEJM
Cancer research and care practices that adversely affect people with the Duffy null phenotype are an underrecognized and widespread source of discrimination against people of African or Arab ancestry.
030
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Anand Patel @anand-88-patel.bsky.social · 23/11/2024
The final version of our Blood Advances manuscript looking at sub-q decitabine in myelofibrosis is out! pubmed.ncbi.nlm.nih.gov/39250708/
071
Reposted by Dr.Uma Borate The Ohio State University / James Cancer Hospital
Mikkael Sekeres @mikkaelsekeres.bsky.social · 23/11/2024
Proud to be the first to follow @beatalleukemia.bsky.social on @bsky.app!!! Join me in following her for outstanding content on leukemia, science, and life!
161